Skip to content

Combinatietherapie van medicijnen en een dieet om remissie te bereiken bij kinderen en jongeren met milde tot matige Colitis Ulcerosa.

Combination Therapy with Drug and Diet for Induction of Remission in Mild to Moderate Active Pediatric Ulcerative colitis: A Single Blinded, International Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON23813
Enrollment
10
Registered
2021-04-21
Start date
2020-10-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Interventions

UC Diet

Sponsors

Amsterdam UMC, locatie AMC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Informed consent 2. Established diagnosis of UC by the Paris classification and Revised Porto Criteria. 3. Age: 10 – 19 years (inclusive) 4. Mild to moderate active disease, 10 = PUCAI =45 5. Extent E2-E4 by the Paris classification 6. Weight >30 kg (ensures that patients who received 5ASA =2 grams are eligible) 7. Stable medication (IMM/ 5ASA) use or no change in medication use for the past 6 weeks. Patients who have received topical 5ASA therapy for <10 days and are active may be included if topical therapy is stopped at enrolment. 8. Patients not receiving 5ASA or using 5ASA<50mg/kg/day

Exclusion criteria

Exclusion criteria: 1. Any proven current infection such as positive stool culture, parasite or C. difficile. 2. Steroids (oral or intravenous) use in the past 3 months. 3. Patients who continue topical 5ASA or steroids after enrolment 4. Use of biologics in present or in past 6 months 5. Use of antibiotics for more than one week in the past 60 days 6. PUCAI >45 7. Acute severe UC in the previous 12 months. 8. Current extra intestinal manifestation of UC. 9. PSC or Liver disease 10. Pregnancy. 11. Vegans or patients unwilling or unable to consume eggs 12. IBD unclassified Exclusion criteria Comments: 1. Stool culture, parasite or C. difficile will only be measured if the patient has diarrhea. 2. Patients who have received treatment enemas for 3 weeks or less then 3 days and are active, can be included but must stop the enemas on the day of enrolment

Design outcomes

Primary

MeasureTime frame
Remission defined as PUCAI<10 at week 6

Secondary

MeasureTime frame
Clinical Secondary End Points: - Response defined as a drop of PUCAI at least 10 points or remission (intention to treat) week 6 . - Mean/median change in Calprotectin at week 6 - Sustained steroid & biologic free remission week 12 - Need for topical therapy by week 12 - Change in UCDEIS at week 12 ( optional) - Tolerance to diet defined by withdrawal from the study because of difficulties with the diet. Translational Secondary End Points: - Changes to the microbiome: diet vs. no diet - Change in microbiome: remission vs. failures - Short chain fatty acids in stool by group week 6

Contacts

Public ContactCharlotte Verburgt

AmsterdamUMC

c.m.verburgt@amsterdamumc.nl0650063243

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)